Prostate Cancer and Prostatic Diseases最新文献

{"title":"Focal therapy for localized prostate cancer: not all that glitters is gold","authors":"Antonio Franco, Jean de la Rosette, Cosimo De Nunzio","doi":"10.1038/s41391-026-01136-1","DOIUrl":"10.1038/s41391-026-01136-1","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 3","pages":"461-463"},"PeriodicalIF":6.9,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41391-026-01136-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148339814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical care","authors":"Anne M. A. Prinsen, Stefan Slagter, Ivo G. Schoots, Geert J. L. H. van Leenders, Harm H. E. van Melick, J. P. Michiel Sedelaar, Diederik M. Somford, Roderick C. N. van den Bergh","doi":"10.1038/s41391-026-01134-3","DOIUrl":"10.1038/s41391-026-01134-3","url":null,"abstract":"Magnetic resonance imaging (MRI), introduced into European (2019) and Dutch (2020) guidelines, reshaped prostate cancer (PCa) diagnostics by altering biopsy indications and strategies. In expert-center studies MRI-based diagnostics reduces biopsy rates and ISUP Grade Group (GG) 1 detection, while maintaining or increasing GG ≥ 2 detection compared to systematic biopsies. We evaluated nationwide biopsy outcomes during MRI adoption in routine practice in the Netherlands. Retrospective nationwide study of histopathology reports from all diagnostic biopsies in men without prior PCa in the Netherlands (2015-2021), retrieved from the Dutch nationwide pathology databank (Palga). Outcomes included annual biopsy volumes and proportions cancer-negative, GG1 and GG ≥ 2 biopsies. MRI-related terminology served as a proxy for MRI use. ISUP GG concordance between biopsy and radical prostatectomy (RP), defined as identical highest GG in biopsy and RP specimen, was assessed. The Mann-Kendall test evaluated monotonic time trends. Among 127,856 biopsies (116,711 men), annual diagnostic biopsy numbers decreased from 18,719 (2015) to 17,094 (2021; -8.7%, p = 0.13). Cancer-negative biopsies declined from 49% to 29% (p = 0.003), while GG ≥ 2 detection increased from 30% to 53% (p = 0.002). GG1 detection minimally decreased (20% to 18%, p = 0.02). MRI terminology in pathology reports increased (8.2% to 51%) and biopsy-RP GG concordance improved (51% to 60%, p = 0.007). Analyses could not adjust for increased opportunistic PSA screening or adjunct diagnostic tool use. Nationwide Dutch pathology data show improved diagnostic efficiency and efficacy over time, with fewer biopsies, fewer cancer-negative biopsies, and increased GG ≥ 2 detection. These findings coincide with rising estimated MRI uptake, suggesting MRI-driven diagnostic improvements.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 4","pages":"892-899"},"PeriodicalIF":6.9,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148332514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"En-bloc vs lobe-by-lobe laser prostatectomy: where do we stand?","authors":"Mahmoud Laymon, Yahya H. Elmorsy, Ahmed M. Elshal, Ahmed R. El-Nahas, Ahmed M. El-Assmy","doi":"10.1038/s41391-026-01130-7","DOIUrl":"10.1038/s41391-026-01130-7","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 3","pages":"655-656"},"PeriodicalIF":6.9,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148318499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to de Riese et al. regarding “methodological and clinical considerations of MRI-based prostate cancer risk calculators”","authors":"Ciarán Courtney O’Toole, Nancy Fosua Boakye, Ailish Hannigan, Amirhossein Jalali","doi":"10.1038/s41391-026-01133-4","DOIUrl":"10.1038/s41391-026-01133-4","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 3","pages":"657-658"},"PeriodicalIF":6.9,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148302768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological and clinical considerations of MRI-based prostate cancer risk calculators","authors":"Werner T. W. de Riese, Aaron De Souza, Chase Renstrom","doi":"10.1038/s41391-026-01129-0","DOIUrl":"10.1038/s41391-026-01129-0","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 3","pages":"654-654"},"PeriodicalIF":6.9,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148302811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial","authors":"Quoc-Dien Trinh, Daniel J. George, Neal Shore, Egils Vjaters, David Olmos, Andrea Juliana P. de Santana Gomes, Augusto Cesar de Andrade Mota, Natasha Littleton, Shankar Srinivasan, Frank Verholen, Kunhi Parambath Haresh, Fred Saad","doi":"10.1038/s41391-026-01131-6","DOIUrl":"10.1038/s41391-026-01131-6","url":null,"abstract":"This analysis reports efficacy and safety data in the subgroup of Black patients from the ARANOTE phase 3 trial. Patients starting on androgen-deprivation therapy (ADT) were randomised 2:1 to receive darolutamide 600 mg twice daily or placebo. Of the total ARANOTE population (N = 669), 65 patients (10%; darolutamide, n = 41; placebo, n = 24) were Black. In Black patients, darolutamide + ADT improved radiological progression-free survival (rPFS), reducing the risk of radiological progression or death by 49% vs ADT alone, consistent with the overall population. In Black patients from ARANOTE, darolutamide was associated with improvement in rPFS.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 3","pages":"646-649"},"PeriodicalIF":6.9,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41391-026-01131-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148295898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials","authors":"Junliang Zhao, Xinyang Cai, Zijun Mo, Diwei Zhao, Jun Wang, Zhenyu Yang, Xingbo Long, Yuanwei Li, Dong Chen, Jitong Li, Zhaohui Zhou, Shigeng Li, Yonghong Li","doi":"10.1038/s41391-026-01128-1","DOIUrl":"10.1038/s41391-026-01128-1","url":null,"abstract":"Cardiovascular disease (CVD) is the leading cause of non-cancer mortality in prostate cancer (PCa) patients. The management of CVD, including hypertension, holds equal significance to cancer treatment. However, the optimal antihypertensive agent for blood pressure management in PCa patients receiving abiraterone acetate (AA) is still unclear. This study aims to investigate the association between various antihypertensive regimens and survival outcomes in PCa patients treated with AA. We performed a post-hoc observational analysis using data from COU-AA-301 and COU-AA-302. Radiographic progression-free survival (rPFS), overall survival (OS) and prostate cancer-specific survival (PCSS) were evaluated using the Kaplan-Meier method. Cox proportional hazards models were used to obtain hazard ratios (HRs) and associated 95% confidence intervals (CIs). Among the AA groups of COU-AA-301 and COU-AA-302, angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) monotherapy was associated with longer rPFS (HR 0.82, 95% CI 0.59–1.13; HR 0.71, 95% CI 0.53–0.95), OS (HR 0.66, 95% CI 0.41–1.06; HR 0.70, 95% CI 0.53–0.92) and PCSS (HR 0.72, 95% CI 0.44–1.19; HR 0.67, 95% CI 0.49–0.92). Multiple-class antihypertensive treatment regimens including ACEI/ARBs were associated with longer rPFS (HR 0.74, 95% CI 0.59–0.92; HR 0.71, 95% CI 0.54–0.94), OS (HR 0.76, 95% CI 0.57–1.01; HR 0.72, 95% CI 0.55–0.94) and PCSS (HR 0.71, 95% CI 0.51–0.99; HR 0.62, 95% CI 0.46–0.83). Multivariable analysis indicated that ACEI/ARBs were associated with improved rPFS (HR 0.72, 95% CI 0.60-0.86; HR 0.75, 95% CI 0.60–0.94), OS (HR 0.71, 95% CI 0.56–0.91; HR 0.70, 95% CI 0.56–0.88) and PCSS (HR 0.73, 95% CI 0.55–0.96; HR 0.64, 95% CI 0.50–0.82). In this post-hoc analysis, concomitant use of ACEI/ARBs was associated with longer rPFS, OS and PCSS in PCa patients treated with AA. The potential role of ACEI/ARB-containing antihypertensive regimens in these patients warrants further investigation. ClinicalTrials.gov Identifier: NCT00638690, NCT00887198","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 4","pages":"875-884"},"PeriodicalIF":6.9,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148240079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zenflow spring system for benign prostatic hyperplasia - 24 month outcomes of the ZEST pilot studies.","authors":"Peter Gilling, Peter Chin, Paul Anderson, Kevin Zorn, Edward D Matsumoto, William Lynch, Lewis Chan, Henry Woo, Rodrigo Pérez Becerra, Janelle Brennan, Dean Elterman","doi":"10.1038/s41391-026-01126-3","DOIUrl":"10.1038/s41391-026-01126-3","url":null,"abstract":"<p><strong>Background: </strong>Benign Prostatic Hyperplasia (BPH) affects more than half of men over age 50, yet current treatment options are limited to medications that cause bothersome side effects or surgical procedures, including minimally invasive surgical therapies (MIST) that involve piercing, cutting, or burning tissue, often leading to discomfort and recovery concerns. The Zenflow Spring System® provides a tissue-preserving alternative that offers symptom relief with quicker recovery and less procedural discomfort.</p><p><strong>Methods: </strong>Three single-arm, multicenter, prospective pilot studies with similar trial designs were conducted from 2018-2021 across four countries and data were combined to evaluate the feasibility, safety, and effectiveness of the Spring System in relieving symptoms of obstructive BPH. Men ≥ 45 years with moderate-to-severe symptoms (International Prostate Symptom Score (IPSS ) >13), peak urinary flow rate (QMax) between 5 and 15 mL/s, prostate volume between 25 and 80 cc, prostatic urethral length between 25 and 45 mm, and voided volume of at least ≥ 125 mL were enrolled. The primary endpoint was symptom improvement 3 months post-procedure, measured by change in IPSS. Secondary endpoints included IPSS-QoL, and functional improvement measured by Qmax. Follow-up visits occurred through 24 months.</p><p><strong>Results: </strong>Successful implantation of the Spring Implant was achieved in all 72 study participants, with no perioperative serious adverse events. At 3 months, mean change from baseline was -10.71 (95% CI: -12.90, -8.51, p < 0.001) for IPSS, -2.1 (95% CI: -2.61, -1.58, p < 0.001) for IPSS-QoL, and 2.86 (95% CI: 1.68, 4.04, p < 0.001) for Qmax, corresponding to 49%, 47%, and 27% improvements, respectively. These improvements were sustained through 24 months, with 48%, 55%, and 32% improvement relative to baseline in IPSS, IPSS-QoL, and Qmax, respectively.</p><p><strong>Conclusions: </strong>At 24-months, treatment with the Spring System resulted in immediate, significant, and durable improvements compared with baseline, supporting its role as a minimally invasive, tissue-preserving treatment option for men with lower urinary tract symptoms secondary to BPH.</p><p><strong>Trial registration: </strong>NCT03595735, NCT03577236, NCT04309695.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148212318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biochemical recurrence after radical prostatectomy: Where do we stand to?","authors":"Rolando Maria D'Angelillo, Luca Eolo Trodella, Michele Fiore, Edy Ippolito, Carlo Greco, Sara Ramella","doi":"10.1038/s41391-026-01125-4","DOIUrl":"https://doi.org/10.1038/s41391-026-01125-4","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights gained from single-cell transcriptomics on the cellular identity and plasticity of prostate epithelial cells.","authors":"Megan Hess Check, Karen S Sfanos","doi":"10.1038/s41391-026-01127-2","DOIUrl":"https://doi.org/10.1038/s41391-026-01127-2","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}